News & Media

Access press releases, presentations, and corporate information.

Press Room

News Releases

01/08/25

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

01/06/25

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

12/20/24

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

12/13/24

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

11/26/24

Neurocrine Biosciences to Participate at Investor Conferences in December

11/26/24

Neurocrine Biosciences to Participate at Investor Conferences in December

11/07/24

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Resources

About Neurocrine Biosciences

Learn About Us and Our Work

Clinical Studies

Check Out What We’re Studying

Pipeline

Check Out What We’re Working On